• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A case of immune thrombocytopenia associated with invasive thymoma successfully treated with eltrombopag.

作者信息

Yoon Jung-Ki, Jang Hee Ryeong, Park Jin Hyun, Kim Ki Hwan, Roh Eu Youn, Byun Ja Min

机构信息

Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.

出版信息

Blood Res. 2019 Mar;54(1):74-79. doi: 10.5045/br.2019.54.1.74. Epub 2019 Mar 21.

DOI:10.5045/br.2019.54.1.74
PMID:30956967
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6439297/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3ad/6439297/03549d9abda5/br-54-74-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3ad/6439297/f2c956ffad7e/br-54-74-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3ad/6439297/880fdcb11d11/br-54-74-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3ad/6439297/03549d9abda5/br-54-74-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3ad/6439297/f2c956ffad7e/br-54-74-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3ad/6439297/880fdcb11d11/br-54-74-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3ad/6439297/03549d9abda5/br-54-74-g003.jpg

相似文献

1
A case of immune thrombocytopenia associated with invasive thymoma successfully treated with eltrombopag.一例侵袭性胸腺瘤相关免疫性血小板减少症经艾曲泊帕治疗成功的病例。
Blood Res. 2019 Mar;54(1):74-79. doi: 10.5045/br.2019.54.1.74. Epub 2019 Mar 21.
2
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.艾曲波帕治疗慢性免疫性血小板减少症（RAISE）：6 个月随机、3 期研究。
Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23.
3
Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.一名难治性原发性免疫性血小板减少症患儿成功停用艾曲泊帕并文献综述
Blood Coagul Fibrinolysis. 2019 Mar;30(2):71-74. doi: 10.1097/MBC.0000000000000794.
4
[Successful treatment of post-allogeneic hematopoietic transplant immune thrombocytopenia with eltrombopag].[艾曲泊帕成功治疗异基因造血干细胞移植后免疫性血小板减少症]
Rinsho Ketsueki. 2018;59(11):2418-2422. doi: 10.11406/rinketsu.59.2418.
5
Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial.免疫性血小板减少症患者围手术期口服艾曲泊帕与静脉注射免疫球蛋白的比较：一项非劣效性、多中心、随机试验
Lancet Haematol. 2020 Sep;7(9):e640-e648. doi: 10.1016/S2352-3026(20)30227-1.
6
A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag.一名原发性免疫性血小板减少症患者经艾曲泊帕治疗后分娩出的无畸形低出生体重婴儿。
Int J Hematol. 2018 Jul;108(1):109-111. doi: 10.1007/s12185-017-2383-1. Epub 2017 Nov 29.
7
Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales.在英格兰和威尔士，艾曲泊帕与罗米司亭治疗慢性免疫性血小板减少症的成本效益
Value Health. 2016 Jul-Aug;19(5):614-22. doi: 10.1016/j.jval.2016.03.1856. Epub 2016 May 11.
8
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.依鲁替尼治疗儿童慢性免疫性血小板减少症（PETIT2）的随机、多中心、安慰剂对照试验。
Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28.
9
Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.艾曲泊帕在一名难治性免疫性血小板减少症儿童中的成功应用：病例报告及文献综述
Blood Coagul Fibrinolysis. 2016 Oct;27(7):825-827. doi: 10.1097/MBC.0000000000000474.
10
Eltrombopag for treatment of thrombocytopenia-associated disorders.艾曲泊帕用于治疗血小板减少相关疾病。
Expert Opin Pharmacother. 2015;16(14):2243-56. doi: 10.1517/14656566.2015.1085512.

本文引用的文献

1
Invasive Thymoma with Pure Red Cell Aplasia and Amegakaryocytic Thrombocytopenia.侵袭性胸腺瘤伴纯红细胞再生障碍和无巨核细胞性血小板减少症。
Hematol Rep. 2016 Dec 9;8(4):6680. doi: 10.4081/hr.2016.6680. eCollection 2016 Nov 2.
2
Thymic Epithelial Tumor-Associated Cytopenia: A 10-Year Observational Study in France.胸腺瘤相关血细胞减少症：法国的一项 10 年观察性研究。
J Thorac Oncol. 2016 Mar;11(3):391-9. doi: 10.1016/j.jtho.2015.11.012. Epub 2016 Jan 4.
3
Thymoma and autoimmunity.胸腺瘤与自身免疫。
Cell Mol Immunol. 2011 May;8(3):199-202. doi: 10.1038/cmi.2010.74. Epub 2011 Feb 14.
4
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.艾曲波帕治疗慢性免疫性血小板减少症（RAISE）：6 个月随机、3 期研究。
Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23.
5
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.艾曲波帕用于治疗慢性特发性血小板减少性紫癜。
N Engl J Med. 2007 Nov 29;357(22):2237-47. doi: 10.1056/NEJMoa073275.
6
Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience.胸腺瘤相关的纯红细胞再生障碍：来自一家机构50年经验的临床见解
Br J Haematol. 2006 Nov;135(3):405-7. doi: 10.1111/j.1365-2141.2006.06295.x.
7
Malignant thymoma complicated by amegakaryocytic thrombocytopenic purpura.恶性胸腺瘤合并无巨核细胞性血小板减少性紫癜。
Eur J Intern Med. 2005 Nov;16(7):523-4. doi: 10.1016/j.ejim.2005.09.005.
8
Thymoma with idiopathic thrombocytopenic purpura: report of a case.
J Thorac Cardiovasc Surg. 2005 Feb;129(2):453. doi: 10.1016/j.jtcvs.2004.06.021.
9
WHO histologic classification is a prognostic indicator in thymoma.世界卫生组织组织学分类是胸腺瘤的一个预后指标。
Ann Thorac Surg. 2004 Apr;77(4):1183-8. doi: 10.1016/j.athoracsur.2003.07.042.
10
Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease.胸腺瘤改变血液中的T细胞亚群组成：胸腺瘤相关自身免疫性疾病的一种潜在机制。
Blood. 2000 Dec 1;96(12):3872-9.